7月26日消息--环球医学据悉，Chimerix公司于7月25日宣布，授予默克公司（在美国和加拿大之外的国家称“默沙东”）执行CMX157许可协议的全球独家权利， 目前正在评估Chimerix公司新研发的脂质无环核苷膦酸酯治疗HIV感染的效果。

根据协议条款，默克公司获得了全球独家授权，将负责正在研究的口服核苷类逆转录酶抑制剂（NRTI）CMX157的开发及商业化。 Chimerix将收到1750万美元的预付款，并有资格获得高达151亿美元里程碑付款以及未来销售的版税。

“这项协议是在我们脂质技术平台的基础上为了满足主要的未满足的医疗需求，Chimerix制定最佳治疗方案任务的一个重要的里程碑，” Chimerix总裁兼首席执行官Kenneth I. Moch说。“默克公司是开发这种药物并帮助我们最大限度地开发CMX157抗艾滋病毒潜力的最理想的合作伙伴。通过许可CMX157所创造的价值，将有助于继续推进我们的先导化合物CMX001通过其关键的3期试验，而我们目前正在计划明年年初开始招募患者。

“默克公司致力于提出的新的治疗HIV/AIDs的方案，”全球传染病、默克研究实验室创始人和副总裁Daria Hazuda说。 “我们期待着与Chimerix的密切合作，以推动开发这种NRTI候选药物。”（环球医学）
 

原文

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection.

Under the terms of the agreement, Merck receives an exclusive worldwide license and will be responsible for development and commercialization of CMX157, an investigational oral nucleoside reverse transcriptase inhibitor (NRTI).  Chimerix will receive a $17.5 million upfront payment and will be eligible to receive up to $151 million in milestones, as well as royalties on future sales.

"This agreement is a significant milestone in Chimerix's mission of developing best-in-class therapies for major unmet medical needs based on our lipid technology platform," said Kenneth I. Moch, President and CEO of Chimerix.  "Merck is the ideal collaborator to develop this drug and help us to maximize the potential of CMX157, given its commitment to its HIV franchise.  The value created through the licensure of CMX157 will help us continue to advance our lead compound, CMX001, through its critical Phase 3 trial, for which we currently plan to begin enrolling patients early next year."             

"Merck is committed to bringing forward new treatment options for patients with HIV/AIDs," said Daria Hazuda, Vice President and Worldwide Discovery Head for Infectious Diseases, Merck Research Laboratories.  "We look forward to working closely with Chimerix to advance development of this NRTI candidate."

 相关链接：http://www.news-medical.net/news/20120724/Merck-Chimerix-sign-license-agreement-for-CMX157-to-treat-HIV-infection.aspx